Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down before the market opened on Thursday . The stock had previously closed at $9.04, but opened at $8.59. Sysmex shares last traded at $8.91, with a volume of 1,823 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Sysmex Stock Performance

The company has a market cap of $5.60 billion, a PE ratio of 23.42 and a beta of 1.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The firm’s 50 day moving average is $8.75 and its 200-day moving average is $9.17.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.28%. The business had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, research analysts anticipate that Sysmex Corporation ADR will post 0.37 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.